CAR-20/19-T Cells in Pediatric Patients With Relapsed/Refractory B Cell ALL


Age Group
0-9 years 10-17 years 18-26 years 27 years and older


Biological treatment cell Biological
CAR-20/19-T cells
Trial Summary & Details
Ages: 1 Year to 39 Years
Condition: Relapsed Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Pediatric Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia

This is a phase 1, interventional, open label, treatment study designed to evaluate the safety and feasibility of infusion of CAR-20/19-T in pediatric and young adult subjects with B cell ALL that have relapsed after prior therapies or refractory disease and are not candidates for curative intent standard therapy. There will be two phases of this study. A dose escalation phase to determine the safe CAR-20/19-T cell dose in patients B-cell ALL. Once the desired dose has been identified there will be a 6-patient dose expansion phase at the specified dose level.

Not yet Recruiting
Medical College of Wisconsin, Milwaukee, WI

Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin
Melissa Schussman